Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Angiopoietin-1
  • Angiopoietin-2
  • Hemangiosarcoma
  • Recombinant Fusion Proteins

abstract

  • Trebananib was well tolerated. Lack of response in the first stage of a Simon 2 stage design led to closure of this study. Prolonged PFS was observed in four pts, lasting 3.4-5.5¬†months.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4699670

Digital Object Identifier (DOI)

  • 10.1007/s00280-015-2689-8

PubMed ID

  • 25672915

Additional Document Info

start page

  • 629

end page

  • 38

volume

  • 75

number

  • 3